肺康复治疗联合环磷酰胺及乙酰半胱氨酸应用于间质性肺炎患者的临床效果

Clinical Effect of Lung Rehabilitation Therapy Combined with Cyclophosphamide and Acetylcysteine in Patients with Interstitial Pneumonia

目的探讨肺康复治疗联合环磷酰胺及乙酰半胱氨酸应用于间质性肺炎患者的临床效果.方法选取2020年7月—2022年2月该院收治的84例间质性肺炎患者,按随机数字表法分为两组,各42例.对照组给予环磷酰胺及乙酰半胱氨酸治疗,观察组在对照组基础上加用肺康复治疗,均持续治疗3个月.对比两组肺功能指标、呼吸困难程度、运动耐力及生活质量.结果治疗前,两组肺功能指标相比,差异无统计学意义(P>0.05);治疗3个月,观察组用力肺活量(FVC)为(2.87±0.42)L、第1秒用力呼气容积(FEV_(1))为(2.35±0.37)L,均大于对照组的(2.50±0.37)L、(1.84±0.32)L,FEV_(1)/FVC为(67.55±7.13)%,高于对照组的(61.11±7.42)%,呼气峰流速为(7.69±2.13)L/s,快于对照组的(5.73±1.38)L/s,组间差异有统计学意义(P<0.05).治疗前,两组改良英国医学研究学会呼吸困难指数量表(mMRC)评分、6 min步行试验(6MWT)距离比较,组间差异无统计学意义(P>0.05);治疗3个月,观察组mMRC评分(1.14±0.20)分低于对照组的(1.75±0.23)分,6MWT距离(362.31±53.42)m长于对照组的(310.92±49.16)m,组间差异有统计学意义(P<0.05).治疗前,两组圣乔治呼吸问卷(SGRQ)评分对比,差异无统计学意义(P>0.05);治疗3个月,观察组SGRQ中疾病影响评分(6.16±1.38)分、活动能力评分(15.23±2.86)分、呼吸症状评分(10.30±1.66)分,分别低于对照组的(8.82±1.54)分、(19.84±2.65)分、(13.32±1.77)分,组间差异有统计学意义(P<0.05).结论肺康复治疗联合环磷酰胺及乙酰半胱氨酸能增强间质性肺炎治疗效果,改善患者肺功能,减轻呼吸困难程度,改善运动耐力,提高生活质量.

Objective To investigate the clinical effect of lung rehabilitation therapy combined with cyclophosphamide and acetylcysteine in patients with interstitial pneumonia.Methods 84 patients with interstitial pneumonia admitted to the hospital from July 2020 to February 2022 were selected and divided into two groups according to the random number table method,with 42 patients in each group.The control group was treated with cyclophosphamide and acetylcysteine,and the observation group was treated with lung rehabilitation therapy on the basis of the control group,with both interventions for 3 months.The lung function index,dyspnea degree,exercise endurance and quality of life of the two groups were compared.Results Before treatment,there was no significant difference in lung function index between the two groups(P>0.05);after 3 months of treatment,the forced vital capacity(FVC)and forced expiratory volume in one second(FEV_(1))were(2.87±0.42)L and(2.35±0.37)L,greater than(2.50±0.37)L and(1.84±0.32)L in the control group,FEV_(1)/FVC was(67.55±7.13)%,higher than(61.11±7.42)%in the control group,and peak expiratory flow was(7.69±2.13)L/s,faster than(5.73±1.38)L/s in the control group,and the differences between the groups were statistically significant(P<0.05).Before treatment,there were no significant differences in modified british medical research council(mMRC)score and 6 minute walking test(6MWT)distance between the two groups(P>0.05);after 3 months of treatment,the mMRC score(1.14±0.20)points in the observation group was lower than(1.75±0.23)points in the control group,and the 6MWT distance(362.31±53.42)m was longer than(310.92±49.16)m in the control group,and the differences between the groups were statistically significant(P<0.05).Before treatment,there was no significant difference in St George's respiratory questionnaire(SGRQ)score between the two groups(P>0.05);after 3 months of treatment,the disease influence score(6.16±1.38)points,activity ability score(15.23±2.86)points and respiratory symptom score(10.30±1.66)points in the observation group were lower than(8.82±1.54)points,(19.84±2.65)points and(13.32±1.77)points in SGRQ in the control group,and the differences between the groups were statistically significant(P<0.05).Conclusion Lung rehabilitation therapy combined with cyclophosphamide and acetylcysteine can enhance the therapeutic effect of interstitial pneumonia,improve the lung function of patients,reduce the dyspnea degree,and improve the quality of life.